Targeted Fortification of Donor Breast Milk in Preterm Infants

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-21
SponsorColumbia University

About this trial

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize that infants receiving targeted fortification of donor breast milk will have improved growth compared to infants receiving standard fortification of donor breast milk.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Premature infants born </= 30 weeks gestational age

Birth Weight </= 1500 grams

Disqualifiers

Parents do no consent to donor milk

Confounders for poor growth such as congenital heart disease, GI diagnoses such as gastroschisis and omphalocele, and or major congenital anomalies

Grade III or IV intraventricular hemorrhage diagnoses prior to randomization

Small for gestational age (<3% on Fenton Growth Curve)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid

    Dietary supplement

    The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.

  • Similac Liquid Protein Fortifier

    Dietary supplement

    For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.

  • Nestle Microlipid

    Dietary supplement

    For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.

  • Medica Nutrition SolCarb

    Dietary supplement

    For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.

  • Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)

    Dietary supplement

    The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.

  • Similac Liquid Protein Fortifier (Targeted Fortification)

    Dietary supplement

    Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.

  • Nestle Microlipid (Targeted Fortification)

    Dietary supplement

    Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk

  • Medica Nutrition SolCarb (Targeted Fortification)

    Dietary supplement

    Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk

  • Analysis with Miris (AB) Human Milk Analyzer

    Other intervention

    For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: ControlOther 5 interventions
Group B: ExperimentalExperimental treatment 5 interventions

Trial outcomes

Primary outcomes

1

Change in weight

Weight change in g/kg/day, z-score value, and change in z-score from week-to-week

Time frame
Up to 11 weeks
2

Change in length

Length change in cm/kg/day, z-score value, and change in z-score from week-to-week

Time frame
Up to 11 weeks
3

Head circumference

Head circumference change in cm/kg/day, z-score value, and change in z-score from week-to-week

Time frame
Up to 11 weeks

Secondary outcomes

1

Total Number of Days of Length of Stay in NICU

Today number of days in the NICU.

Time frame
Up to 1 year
2

Rate of Mortality

Rate of morality during NICU hospitalization.

Time frame
Up to one year
3

Number of Feeding Intolerance Events

The number of feeding intolerance events, defined as 1 or more feeds held.

Time frame
Up to 34 weeks corrected gestational age
4

Number of Necrotizing Enterocolitis Events

Number of necrotizing enterocolotis events.

Time frame
Up to 1 year of age

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.